Combination Trial of Tipifarnib and Alpelisib in Adult Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

December 7, 2021

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
HNSCC
Interventions
DRUG

Tipifarnib

Oral administration

DRUG

Alpelisib

Oral administration

Trial Locations (11)

10065

Memorial Sloan Kettering Cancer Center, New York

15232

UPMC Hillman Cancer Center, Pittsburgh

21201

University of Maryland School of Medicine (Marlene and Stewart Greenebaum Comprehensive Cancer Center), Baltimore

21231

Johns Hopkins University School of Medicine (Sidney Kimmel Comprehensive Cancer Center), Baltimore

32827

Lake Nona DDU (Florida Cancer Specialists), Orlando

53792

University of Wisconsin Carbone Cancer Center, Madison

63110

Washington University, School of Medicine, St Louis

75390

UT Southwestern Medical Center (Harold C. Simmons Comprehensive Cancer Center), Dallas

77030

University of Texas MD Anderson Cancer Center, Houston

91010

City of Hope Comprehensive Cancer Center, Duarte

02215

Dana-Farber Cancer Institute (Head and Neck Cancer Treatment Center), Boston

Sponsors
All Listed Sponsors
lead

Kura Oncology, Inc.

INDUSTRY